NASDAQ:IDXG - Interpace Diagnostics Group Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.96 +0.03 (+3.23 %)
(As of 03/20/2019 06:00 AM ET)
Previous Close$0.93
Today's Range$0.9320 - $0.9675
52-Week Range$0.76 - $1.78
Volume255,926 shs
Average Volume206,087 shs
Market Capitalization$27.45 million
P/E RatioN/A
Dividend YieldN/A
Interpace Diagnostics Group, Inc. is an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.

Receive IDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Services
Current SymbolNASDAQ:IDXG



Sales & Book Value

Annual Sales$15.90 million
Book Value$1.48 per share


Net Income$-12,210,000.00


Market Cap$27.45 million
Next Earnings DateN/A
OptionableNot Optionable

Interpace Diagnostics Group (NASDAQ:IDXG) Frequently Asked Questions

What is Interpace Diagnostics Group's stock symbol?

Interpace Diagnostics Group trades on the NASDAQ under the ticker symbol "IDXG."

How were Interpace Diagnostics Group's earnings last quarter?

Interpace Diagnostics Group Inc (NASDAQ:IDXG) announced its quarterly earnings data on Thursday, August, 9th. The business services provider reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.02. The business services provider had revenue of $5.50 million for the quarter, compared to the consensus estimate of $4.80 million. Interpace Diagnostics Group had a negative net margin of 64.40% and a negative return on equity of 33.67%. View Interpace Diagnostics Group's Earnings History.

What price target have analysts set for IDXG?

4 brokers have issued 1 year price targets for Interpace Diagnostics Group's stock. Their forecasts range from $2.25 to $4.00. On average, they expect Interpace Diagnostics Group's share price to reach $3.3125 in the next twelve months. This suggests a possible upside of 245.1% from the stock's current price. View Analyst Price Targets for Interpace Diagnostics Group.

What is the consensus analysts' recommendation for Interpace Diagnostics Group?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Interpace Diagnostics Group in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Interpace Diagnostics Group.

What are Wall Street analysts saying about Interpace Diagnostics Group stock?

Here are some recent quotes from research analysts about Interpace Diagnostics Group stock:
  • 1. HC Wainwright analysts commented, "Our 12-month price target is derived from an estimated market value of the firm at $120M. This includes a discounted cash flow analysis based asset value for the company’s three commercialized laboratory-developed tests (LDTs), with a 15% discount rate and a 2% terminal growth rate, and assuming 39M shares outstanding at the end of 2019." (2/20/2019)
  • 2. According to Zacks Investment Research, "Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company's test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM). Interpace Diagnostics Group Inc, formerly known as PDI Inc., is headquartered in Parsippany, New Jersey. " (1/9/2019)
  • 3. Maxim Group analysts commented, "Interpace Diagnostics announced the publication of a paper titled “The Incremental Value of DNA November issue of Gastrointestinal Endoscopy. The study supports the use of PancraGEN testing on patients who have pancreatic cysts with worrisome features (WFs)." (11/26/2018)

Has Interpace Diagnostics Group been receiving favorable news coverage?

Media headlines about IDXG stock have trended negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Interpace Diagnostics Group earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned media stories about the business services provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.

Who are some of Interpace Diagnostics Group's key competitors?

What other stocks do shareholders of Interpace Diagnostics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Diagnostics Group investors own include Genocea Biosciences (GNCA), Synergy Pharmaceuticals (SGYP), SCYNEXIS (SCYX), Trevena (TRVN), Advanced Micro Devices (AMD), AVEO Pharmaceuticals (AVEO), Novavax (NVAX), Verastem (VSTM), Micron Technology (MU) and Magnegas Applied Tchnlgy Sltns (MNGA).

Who are Interpace Diagnostics Group's key executives?

Interpace Diagnostics Group's management team includes the folowing people:
  • Jack E. Stover, President, Chief Executive Officer & Director
  • Glenn Gershon, Senior Vice President-Operations
  • James Early, Chief Financial Officer. Secretary & Treasurer
  • Sydney D. Finkelstein, Chief Scientific Officer
  • Sara A. Jackson, Vice President-Clinical Development

Who are Interpace Diagnostics Group's major shareholders?

Interpace Diagnostics Group's stock is owned by many different of institutional and retail investors. Top institutional investors include Essex Investment Management Co. LLC (1.19%), Essex Investment Management Co. LLC (1.19%), Virtu Financial LLC (0.31%) and Wealthsource Partners LLC (0.12%). View Institutional Ownership Trends for Interpace Diagnostics Group.

Which major investors are selling Interpace Diagnostics Group stock?

IDXG stock was sold by a variety of institutional investors in the last quarter, including Wealthsource Partners LLC. View Insider Buying and Selling for Interpace Diagnostics Group.

Which major investors are buying Interpace Diagnostics Group stock?

IDXG stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Essex Investment Management Co. LLC and Virtu Financial LLC. View Insider Buying and Selling for Interpace Diagnostics Group.

How do I buy shares of Interpace Diagnostics Group?

Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Interpace Diagnostics Group's stock price today?

One share of IDXG stock can currently be purchased for approximately $0.96.

How big of a company is Interpace Diagnostics Group?

Interpace Diagnostics Group has a market capitalization of $27.45 million and generates $15.90 million in revenue each year. The business services provider earns $-12,210,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

What is Interpace Diagnostics Group's official website?

The official website for Interpace Diagnostics Group is

How can I contact Interpace Diagnostics Group?

Interpace Diagnostics Group's mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]

MarketBeat Community Rating for Interpace Diagnostics Group (NASDAQ IDXG)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  213 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  367
MarketBeat's community ratings are surveys of what our community members think about Interpace Diagnostics Group and other stocks. Vote "Outperform" if you believe IDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/20/2019 by Staff

Featured Article: Hedge Funds Explained

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel